Source: Wikipedia.
Background
Based in Denmark, Novo Nordisk (NVO) is a focused pharmaceutical company with leading positions in chronic diseases, such as diabetes, obesity, hemophilia, and growth hormone.
The company is truly a secular growth engine as it rides the megatrend in global pandemics of diabetes and obesity, both of which, in aggregate, are contributing roughly 85% of the total sales at the moment. The shareholders of Novo Nordisk should see a long runway ahead for further business expansion, thanks to the continuous growth of the total market as well as the